Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,051.03 0.17 (0.02%) as of 4:30 Fri 6/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.03(B)
Last Volume: 750,617 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 42 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Yancopoulos George President and CSO   •       •      –    2017-12-19 4 GA $0.00 $0 I/I 242,150 486,820     -
   Yancopoulos George President and CSO   •       •      –    2017-12-19 4 GD $0.00 $0 D/D 242,150 847     -
   Yancopoulos George President & CSO   •       •      –    2017-12-18 4 D $386.90 $99,762,165 D/D (257,850) 422,762     -
   Yancopoulos George President and CSO   •       •      –    2017-12-14 4 GA $0.00 $0 I/I 89,264 244,670     -
   Yancopoulos George President and CSO   •       •      –    2017-12-14 4 GD $0.00 $0 D/D 89,264 500,847     -
   Schleifer Leonard S President & CEO   •       •      –    2017-12-13 4 D $385.08 $52,300,025 D/D (135,816) 271,593     -
   Schleifer Leonard S President & CEO   •       •      –    2017-12-13 4 OE $21.92 $5,480,000 D/D 250,000 407,409     -
   Yancopoulos George President & CSO   •       •      –    2017-12-13 4 D $385.08 $40,885,484 D/D (106,174) 680,612     -
   Yancopoulos George President & CSO   •       •      –    2017-12-13 4 OE $21.92 $4,284,001 D/D 195,438 786,786     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-12-11 4 D $383.29 $32,067,958 D/D (83,665) 399,847     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-12-11 4 OE $21.92 $3,375,000 D/D 153,969 483,512     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-11-07 4 GD $0.00 $0 I/I 91 149,717     -
   Brown Michael S Director   –       •      –    2017-10-05 4 AS $475.00 $712,500 D/D (1,500) 0     -
   Brown Michael S Director   –       •      –    2017-10-05 4 OE $177.82 $266,730 D/D 1,500 1,500     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-10-03 4 GD $0.00 $0 I/I 477 149,808     -
   Baker Charles A Director   –       •      –    2017-09-29 4 AS $450.00 $900,000 D/D (2,000) 9,000     -
   Baker Charles A Director   –       •      –    2017-09-29 4 OE $18.61 $37,220 D/D 2,000 11,000     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-09-06 4 AS $496.51 $235,873 D/D (474) 7,099     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-09-05 4 AS $500.33 $94,700 D/D (189) 7,573     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-09-01 4 D $501.29 $1,171,515 D/D (2,337) 7,762     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-09-01 4 OE $272.70 $818,100 D/D 3,000 10,099     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-08-31 4 AS $487.88 $210,693 D/D (427) 7,099     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-08-30 4 D $486.91 $765,909 D/D (1,573) 7,526     -
   Landry Robert E SVP Finance & CFO   •       –      –    2017-08-30 4 OE $272.70 $545,400 D/D 2,000 9,099     -
   Sanofi-Aventis   •       •       •   2017-08-25 4 B $479.19 $34,840,133 I/I 72,378 23,880,537 2.64     -
  2430 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 42 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us